Evidence map›Paper›PMID 38458638›Full record

ArticleJournal for immunotherapy of cancer2024

Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells.

Monica Parodi, Giovanni Centonze, Fabio Murianni, Paola Orecchia, Francesca Andriani, Ilaria Roato, Cecilia Gardelli, Melissa Balsamo, Massimo Moro, Giulia Taiè and 8 more

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026
    Review
  12. Review
  13. Review
  14. Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  15. Article
  16. Article
  17. CD56Journal for immunotherapy of cancer · 2025
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Monica ParodiImmunology Operative Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Giovanni CentonzeUnit of Epigenomics and Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Fabio MurianniUnit of Epigenomics and Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Paola OrecchiaImmunology Operative Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Francesca AndrianiUnit of Epigenomics and Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Ilaria RoatoC.I.R Dental School, Department of Surgical Sciences, University of Turin, Torino, Italy.
Cecilia GardelliUnit of Epigenomics and Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Melissa BalsamoUnit of Epigenomics and Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Massimo MoroUnit of Epigenomics and Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Giulia TaièUnit of Epigenomics and Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Ugo PastorinoThoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Andrea PetrettoCore Facilities, Clinical Proteomics and Metabolomics, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Chiara LavarelloCore Facilities, Clinical Proteomics and Metabolomics, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Massimo MilionePathology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Gabriella SozziUnit of Epigenomics and Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Luca RozUnit of Epigenomics and Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy giulia.bertolini@istitutotumori.mi.it luca.roz@istitutotumori.mi.it massimo.vitale@hsanmartino.it.ORCID 0000-0001-5817-7149
Massimo Vitale *Immunology Operative Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy giulia.bertolini@istitutotumori.mi.it luca.roz@istitutotumori.mi.it massimo.vitale@hsanmartino.it.
Giulia Bertolini *Unit of Epigenomics and Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy giulia.bertolini@istitutotumori.mi.it luca.roz@istitutotumori.mi.it massimo.vitale@hsanmartino.it.ORCID 0000-0002-8495-4594
Fondazione IRCCS Istituto Nazionale dei Tumori · ITOspedale Policlinico San Martino · ITIstituto Giannina Gaslini · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpithelial to mesenchymal transition (EMT) endows cancer cells with pro-metastatic properties, which appear most effective when cells enter an intermediate hybrid (H) state, characterized by integrated mesenchymal (M) and epithelial (E) traits. The reasons for this advantage are poorly known and, especially, it is totally unexplored whether the interplay between H-cells and NK cells could have a role. Here we characterize the pro-metastatic mechanics of non-small cell lung cancer (NSCLC) H-cells and their subset of cancer-initiating cells (CICs), dissecting crucial interactions with NK cells.

methodsHuman lung cancer cell lines and sublines representative of E, M, or H states, assessed by proteomics, were analyzed in vivo for their tumor-forming and disseminating capabilities. Interactions with NK cells were investigated in vitro using migration assays, cytotoxic degranulation assays, and evaluation of CD133+ CICs modulation after coculture, and validated in vivo through NK cell neutralization assays. Correlation between EMT status, NK cell infiltration, and survival data, was evaluated in a cohort of surgically resected NSCLC cases (n=79).

resultsWe demonstrated that H-cells, have limited dissemination capability but show the highest potential to initiate metastases in vivo. This property was related to their ability to escape NK cell surveillance. Mechanistically, H-cells expressed low levels of NK-attracting chemokines (CXCL1 and CXCL8), generating poorly infiltrated metastases. Accordingly, proteomics and GO enrichment analysis of E, H, M cell lines showed that the related secretory processes could change during EMT.Furthermore, H-CICs uniquely expressed high levels of the inhibitory ligand B7-H3, which protected H-CIC from NK cell-mediated clearance. In vivo neutralization assays confirmed that, indeed, the pro-metastatic properties of H-cells are poorly controlled by NK cells.Finally, the analysis of patients revealed that detection of hybrid phenotypes associated with low NK infiltration in NSCLC clinical specimens could identify a subset of patients with poor prognosis.

conclusionsOur study demonstrates that H-cells play a central role in the metastatic spread in NSCLC. Such pro-metastatic advantage of H-cells is supported by their altered interaction with NK cells and by the critical role of B7-H3 in preserving their H-CIC component, indicating B7-H3 as a potential target in combined NK-based therapies.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsEpithelial-Mesenchymal TransitionHumansKiller Cells, NaturalTranscription FactorsTranscription FactorsImmunity, InnateKiller Cells, NaturalNon-Small Cell Lung CancerReceptors, AntigenTumor Escape

Identifiers

PMID38458638
PMCPMC10921513
OpenAlexW4392594086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.